Passage Bio

Passage Bio, Inc is a biotechnology company developing genetics-based medicines.

P/E

Net profit

P/B

Book value

P/FCF

FCF

Yield

Growth potential

Report period	2018	2019	2020	2021	2022	Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Report period	2018	2019	2020	2021	2022	Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Ticker	Name	Type	Nominal value	ISIN	Price
PASG:US	Passage Bio	Common share	-	US7027121000	$1.15

Passage Bio news

16.05.2022

Passage Bio's GAAP loss for 3 months of 2022 was $42.811 million, up 10.1% from $38.882 million in the previous year.

Source:

03.03.2022

Passage Bio's GAAP loss for 2021 was $185.386 million, up 65.2% from $112.232 million the previous year.

Source:

04.11.2021

Passage Bio's GAAP loss for 9M 2021 was $134.232 million, up 83.2% from $73.288 million in the prior year.

Source:

05.08.2021

Passage Bio's GAAP loss for six months of 2021 was $87.317 million, up 95.1% from $44.757 million in the previous year.

Source:

General information

Company name	Passage Bio
Sector	Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Website	www.passagebio.com

Passage Bio balance sheet